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ABSTRACT
Despite the increased number of cadaver donors and overall organ transplantations, we
have observed a dramatic increase in the waiting list. We evaluated transplantations
performed using marginal (n  63) and “ideal” or optimal donors (n  86). Donor and
recipient functional and histopathological data were studied at 1 and 5 years after
transplantation. Among the marginal donor group, we investigated whether the age or
pre-existent hypertension in the donor showed a strong impact on the functional
deterioration of the grafts. Twenty-three graftectomies were performed in marginal, and
39 in ideal recipients (P  .002). Evaluating graft function, at 5 years, we observed the
serum creatinine level (P  .0001) and the estimated glomerular filtration rate (P  .003)
are significantly different between the two groups. At this time there was a significant
difference in the serum creatinine level of patients who were older than the age of 55 years
compared with those who showed hypertension (P  .0003). Evaluating morphological
changes in the kidneys, acute rejection episodes (P .0004) and interstitial fibrosis/tubular
atrophy (P  .002) were significantly greater among the marginal versus the ideal groups.
At 1 year after kidney transplantation, despite no significant difference regarding renal






wTHE end-stage renal disease (ESRD) population isincreasing worldwide; in Europe has doubled during
the past decade.1,2 ESRD patients either remain on dialysis
or undergo renal transplantation, which is a more beneficial
treatment for various reasons. Despite the increased num-
ber of cadaver donors and overall organ transplantations,
the waiting list has shown a dramatic increase. Because of
the shortage of organs available for transplantation, mar-
ginal donors are now accepted to increase the donor pool.
We have performed transplantations using marginal
(MDK) and ideal donor kidneys (IDK).3 Increased donor
ge is a major determinant of graft outcome4,5; the number
f older cadaver donors (50 years) as a fraction of all
rocedures in Hungary has increased from 12.5% in 1995 to
5.3% in 2005. Although there is no universal definition an
deal versus marginal kidneys the latter ingener believed to
isplay one or more of the following pretransplantation
actors: donor age  55 years; non–heart-beating donor
NHBD); cold ischemia time (CIT)  36 hours and/or
donor hypertension or diabetes mellitus of  10-year
duration.5,6 Allograft outcomes with marginal kidneys turn
to be inferior to those of organs considered to be ideal.7,8Notwithstanding the diminished graft survival of marginal
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Transplantation Proceedings, 44, 2139–2142 (2012)idneys, renal transplantation improves the quality of life5
and an economic analysis suggested that transplantation
with a marginal donor kidney was more cost-effective than
dialysis treatment.8 Improved patient survival is a well-
established benefit of renal transplantation, but the magni-
tude of increased longevity is not uniform among patient
subgroups.5,9 The rapidly growing organ transplantation list
nd increasing mortality of waiting patients have prompted
nterest in the use of organs from marginal donors.
The aim of our study was to evaluate the survival of
idney grafts from marginal or ideal donors, as well as their
unctional and histopathological changes. We examined
hether there was a significant difference in the function
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2140 BORDA, SZEDERKÉNYI, SZENOHRADSZKY ET ALand/or morphology of grafts from the two groups at 1 or 5
years after transplantation.
PATIENTS AND METHODS
Patients who received a cadaver donor renal transplant were
divided into two groups—marginal (MDK) or ideal (IDK)—
recipients bases on the characteristics of the organ. A recipient was
defined as receiving an MDK if one or more of the following
pretransplantation factors was present: donor age  55 years,
onor history of hypertension longer than 10 years duration, donor
istory of diabetes mellitus longer than 10 years duration, NHBD
r CIT 36 hours. We defined a cadaver kidney transplantation in
hich none of the listed factors was evident as an IDK. From
anuary 1, 2005, to December 31, 2009, we performed 249 kidney
ransplantations using 63 marginal and 186 ideal kidneys. The
arginal group included 2 NHBDs, 3 CIT more than 36 hours, 27
ypertensive donors, and 31 who were older than 55 years.
The following data were examined in our study: gender, creati-
ine levels diuresis in the last 24 hours CIT, HLA-mismatch, cause
f death, and recipient age.
Functional and histopathological changes regarding serum cre-
tinine and estimated glomerular filtration rate (eGFR) were
tudied in the two patient groups at 1 and 5 years by measuring
unctional and histopathological changes, serum creatinine levels,
nd eGFR, using the Cockroft-Gault formula. We evaluated
hether the age of or hypertension in the marginal donor acceler-
ted the functional deterioration of the graft.
Histopathological changes in the grafts were evaluated using a
rotocol biopsy at 1 year after transplantation in 102 cases. Before
he transplantation, a (“zero biopsy”) histological sample was ob-
ained before implantation using a 16-G Tru-Cut needle and a biopsy
un. Morphological examinations included light microscopic staining
hematozylin and eosin stain, periodic acid-Schiff trichrome, and
ethenamine silver), as well as immunofluorescence analysis of
rozen sections using antibodies to HLA class II antigens, comple-
ent components 4d (C4d) and C3, immunoglobulin G (IgG), IgA,
nd IgM. Embedding for electron microscopy was performed in all
ases with ultrastructural evaluation. Renal lesions were graded
ccording to the 2003 modification of the Banff ’97 classification.
istological changes involved acute rejection (AR), calcineurin
nhibitor toxicity (CNI-tox), interstitial fibrosis/tubular atrophy
IF/TA) grades II and III, (grade I was considered normal),
Table 1. Donor and Recipient Data
Data
MDK (n  63;
Mean  SD)









107.60  173.100 90.83  32.093 .003
Urine production in
the last 24 h
5531  2805 5789  3086 .156
CIT (h) 17.502  3.821 17.193  4.081 .125
Recipient’s age (y) 53.94  8.15 40.81  6.86 .002
Causes of death
Stroke 29 (46.0%) 52 (28.0%) .0001
SAB 7 (11.1%) 41 (22.0%) .245
Trauma 11 (17.5%) 64 (34.4%) .001
Other 16 (25.4%) 29 (15.6%) .057Abbreviations: MDK, marginal donor kidney; IDK, ideal donor kidney; CIT,
cold ischemia time; SAB, subarachnoid bleeding.yelonephritis (PN), and other changes (acute tubular necrosis,
lomerulonephritis, and BK polyomavirus nephritis.10
Our study was approved by the Regional Human Biomedical
Research Ethics Committee (Reg. No.: 123/2010). Each patient
was provided with comprehensive information regarding the study.
Statistical Analysis
Descriptive statistics were used to assess donor and recipient data.
As the distribution of samples was mostly non-normal by the
Kolmogorov-Smirnov test, we used the Mann-Whitney test to
compare marginal versus ideal kidney recipients. Two group com-
parisons for categorical data used the chi-square or Fisher exact
tests. The multivariable dependences of acute rejection episodes
and IF/TA were analyzed using logistic regression. The level of
significance was set at P  .05. SPSS version 15.0 (2007 SPSS Inc.)
was used for statistical analysis.
RESULTS
In our study, graftectomy was performed in 23 (36.5%) of
the 63 (25.3%) marginal patients and in 39 (20.9%) of 186
(74.7%) ideal recipients (P  .002). Four (6.3%) MDK
patients and 20 (10.8%) IDK patients died with functioning
grafts (P  .223; chi-square test).
The creatinine levels of marginal versus ideal donors
were 107.60  173.100 mol/L versus 90.83  32.093
mol/L (P  .003) and mean recipient ages, 53.94  8.15
versus 40.81  6.86 years (P  .002) were significantly
Fig 1. Changes in serum creatinine level in the marginal donor
Table 2. eGFR and Serum Creatinine Levels at First and Fifth
Posttransplantation Years in the MDK and IDK Groups
MDK IDK P Value
1 year after Tx
eGFR (mL/min/
1.73 m2)
51.06  18.52 53.75  16.57 .151
se. creatinine
(mol/L)
145.65  63.88 132.78  58.62 .200
5 year after Tx
eGFR (mL/min/
1.73 m2)
39.92  14.49 54.54  16.32 .003
S.Cr (mol/L) 252.36  122.83 171.45  93.72 .0001
Abbreviations: MDK, marginal donor kidney; IDK, ideal donor kidney; Tx,
transplantation; eGFR, estimated glomerular filtration rate; SCr, serum creati-




































KIDNEYS FROM MARGINAL DONORS 2141different. Stroke was the cause of death in 46.0% of MDK
patients and 28.0% of IDK patients (P  .0001). Seventeen
point five percent of MDK patients and 34.4% of IDK
patients died of trauma (P  .001) and the difference was
ignificant in both patient groups. There were no significant
ifferences in HLA mismatch, the last 24-hour diuresis, and
IT (Kolmogorov-Smirnov test; Table 1).
Examination of graft function at 1 year after transplan-
ation revealed comparable serum creatinine levels (P 
200) and eGFR (P  .151) mean values among MDK
ersus IDK patients. In contrast, at 5 years after the
ransplantation, they were significantly different serum cre-
tinine levels were 252.36  122.83 versus 171.45  93.72
mol/L (P  .0001) and eGFRs were 39.92  14.49 versus
4.54  16.32 mL/min/1.73 m2 (P  .003; Mann-Whitney
est; Table 2; Fig 1). At 1 year after the transplantation,
either the serum creatinine level (P .124), nor the eGFR
P  .436) differed significantly whether the MDK donor
was hypertensive or aged. At 5 years the mean serum
creatinine level of MDK patients older than of 55 years was
298.58  66.4 mol/L, whereas that of hypertensive MDK
atients was 184.38  62.86 mol/L (P  .0003; Mann-
Whitney test; Table 3).
Morphologic changes were analyzed in MDK and IDK
patients. Both occurrence of an acute rejection episode
(28.5% versus 6.7%; P .0004) and of IF/TA (17.9% versus
9.5%; P  .002) were significantly greater among MDK.
Normal histological findings were observed significantly
more often among IDK versus MDK groups 60.8% versus
25% (P  .0001). However, there were no significant
differences; in CNI-toxicity, PN, or other histological
changes (Fisher exact test; Table 4). MDK produced a 22%
Table 3. eGFR and Serum Creatinine Levels at First and Fifth
Post transplantation Year in MDK >55 Years and in the MDK
Hypertension Groups
MDK  55 Years
MDK
Hypertension P Value
1 year after Tx
eGFR (mL/min/
1.73 m2)
50.15  19.28 52.64  17.48 .436




41.20  22.72 47.80  18.20 .174
SCr (mol/L) 298.58  66.45 184.38  62.86 .0003
Abbreviations: MDK, marginal donor kidney; IDK, ideal donor kidney; Tx,
transplantation; eGFR, estimated glomerular filtration rate; SCr serum creati-
nine.
Table 4. Protocol Biopsy Res
AR n (%) IF/TA n (%) CNI-to
MDK 8 (28.5%) 5 (17.9) 3 (1
IDK 5 (6.7) 7 (9.5) 5 (6
P value .0004 .002 .1Abbreviations: MDK, marginal donor kidney; IDK, ideal donor kidney; AR, acute re
toxicity.ncreased risk of developing an AR episode, and in 26%
ncrease in the risk of developing IF/TA (Table 5).
DISCUSSION
We followed the courses of kidneys from 25.3% marginal
and 74.7% ideal donors among our recipients between 2005
and 2009. The ratio of MKDs was only 12.5% in the 1990s,
but it has continuously increased due to expansion of donor
criteria to address the rapid increase in the number of
waiting patients. We observed that the ratio of graftecto-
mies between the two groups was significantly different
(P .002) consistent with the literature. Ojo et al5 reported
35.9% graftectomy in an MDK versus 24.9% in the IDK
group (P  .001). Gopalakrishnan et al1 published ratios of
7% versus 25%.11 Evaluating donor and recipient data we
bserved that the creatinine level of the donors (P  .003),
ccurrence of stroke (P  .0001) or trauma (P  .001) as
cause of death as well as recipient age were significantly
different between the two groups. In the study of Ojo et al.5
Recipients age was significantly different between the MDK
and IDK patients (47  13.2 years versus 43  13.8 years;
 .001). Younger renal transplant recipients often outlive
their allografts adding to the waiting list; whereas older
recipients may die before their allograft fails. Introducing a
new method to assess the survival of marginal cadaver
kidneys, has Baskin-Bey et al12 proposed a deceased donor
core (DDS). Rather than defining a donor as meeting
xpanded criteria the DDS seeks to be a quantitative
pproach providing a continuum scale from 0 to 39. The
eceased donor kidney is assigned one of four grades (A, B,
, or D). They reported that a significant number of
adaver donor kidneys (10.7%) that were identified by the
DS system as likely to have decreased posttransplantation
unction and graft survival were missed by the ECD system,
uggesting DDS to display greater predictive ability. We
tudied renal function similar to Eytan et al7 and Persson et
al3 at 1 year after transplantation: there were no significant
differences in the serum creatinine levels or eGFR between
the two groups. However, at 5 years, the serum creatinine
level (P  .0001) and eGFR (P  .003) were significantly
different.13,14 We evaluated whether hypertension or ad-
anced age influenced graft function among the MDK
roup. At 5 years after transplantation, the serum creati-
ine level was significantly greater among patients older
han 55 years compared with hypertensive patients, as
reviously suggested by other authors.15,16
Based on the histopathological changes at 1 year after the
transplantation, AR and IF/TA seemed to be significantly
in the MDK and IDK Groups
) Other n (%) Normal n (%) Total n (%)
5 (17.9) 7 (25) 28 (100)


















2142 BORDA, SZEDERKÉNYI, SZENOHRADSZKY ET ALdifferent in MDK compared with IDK patients although
there was no significant difference in renal function.17
Analyzing 937 first and second cadaver transplants Matas et
al sought to determine whether information available at the
time of an offer could be used to predict long-term graft
survival. The questions voiced by ideal recipients whether
they should accept a marginal kidney provided the back-
ground for their study.18 These studies have suggested that
here is no functional difference between kidneys from
arginal donors and from ideal donors at 1 year after the
ransplantation, although they are evident at 5 years.
Regarding the lower quality of life of patients undergoing
ialysis and the lower long-term survival compared with
hese receiving a kidney from marginal donors, we have
oncluded that expanded donor criteria have enabled more
atients to undergo transplantation, and thus improving
heir quality of life and long-term survival. Further studies
re needed to establish whether there is a significant
ifference in the 10-year graft survival between grafts from
arginal versus ideal donors and to define differences in
unction and morphology.
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